LONDON, July 2 (newratings.com) - Analysts at Panmure Gordon reiterate their "buy" rating on Immunodiagnostic Systems (ticker: LWX). The target price has been raised from 274p to 385p.
In a research note published this morning, the analysts mention
that the company has launched a fully automated immunoassay for the bone formation market, PINP. The launch is in-line with Immunodiagnostic's strategy and would help the company create a niche for itself, the analysts say. The company has reported in-line trading for the first two months of the current fiscal.
© 2009 New Ratings
Send Article by Email
Send Article by IM
Blog This with Y! 360
Printable View
